Glancy prongay & murray llp announces investigation on behalf of acer therapeutics inc. investors (acer)

Los angeles--(business wire)--glancy prongay & murray llp (“gpm”) announces an investigation on behalf of acer therapeutics inc. (“acer” or the “company”) (nasdaq: acer) investors concerning the company and its officers’ possible violations of federal securities laws. if you are a shareholder who suffered a loss, click here to participate. if you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact lesley portnoy, esquire, at 310-201-9150, toll-free at 888-773-9224, or by email to shareholders@glancylaw.com, or visit our website at www.glancylaw.com. on june 25, 2019, the company revealed a complete response letter (“crl”) from the u.s. food and drug administration regarding its marketing application for edsivo, a medication for the treatment of ehlers-danlos syndrome. according to the crl, “an adequate and well-controlled trial” was required to determine whether edsivo “reduces the risk of clinical events” in patients with vascular ehlers-danlos syndrome. on this news, the company’s share price fell $15.16, or nearly 79%, to close at $4.12 on june 25, 2019, thereby injuring investors. if you purchased acer securities, have information, or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact lesley portnoy, of gpm, 1925 century park east, suite 2100, los angeles, ca 90067 at 310-201-9150, toll-free at 888-773-9224, or visit our website at www.glancylaw.com. if you inquire by email please include your mailing address, telephone number, and the number of shares purchased. this press release may be considered attorney advertising in some jurisdictions under the applicable law and ethical rules.
ACER Ratings Summary
ACER Quant Ranking